GEOVAX, INC.
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
- Conditions
- LeukemiaHematopoietic and Lymphoid System NeoplasmCOVID-19 InfectionLymphomaPlasma Cell Myeloma
- Interventions
- Biological: COVID-19 VaccineOther: Diagnostic Laboratory Biomarker AnalysisBiological: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04977024
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
🇺🇸U Mass Chan Medical School, Worcester, Massachusetts, United States
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1Drug: Placebo Administration
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT04639466
- Locations
- 🇺🇸
Millennium Clinical Trials, Thousand Oaks, California, United States
🇺🇸EmVenio Research, Claremont, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03754933
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Winship Cancer Institute - Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
- Conditions
- HIV-1 Infection
- Interventions
- Biological: JS7 plasmid DNA and MVA62B vaccine
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GeoVax, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01378156
- Locations
- 🇺🇸
AIDS Research Alliance, Los Angeles, California, United States
🇺🇸The University of Alabama at Birmingham Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States